Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report - 27/02/24

Doi : 10.1016/j.urology.2023.11.019

Kristin Weiss ^a,^{^{1
Kristin Weiss and Obafunbi Abimbola are co-first authors.}}, Obafunbi Abimbola ^b,^{^{1
Kristin Weiss and Obafunbi Abimbola are co-first authors.}}, Kelsey Miller ^c, William Y. Kim ^d,^e,^f,^g, Tracy L. Rose ^d,^f, Marc A. Bjurlin ^b,^d, Kathryn H. Gessner ^b,^⁎
^a University of North Carolina School of Medicine, Chapel Hill, NC
^b Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC
^c Department of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
^d Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
^e Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC
^f Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
^g Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC

^⁎Address correspondence to: Kathryn Hacker Gessner, M.D., Ph.D., UNC School of Medicine, Department of Urology, Physicians Office Building, 170 Manning Drive, Campus Box #7235, Chapel Hill, NC 27599-7235.UNC School of Medicine, Department of UrologyPhysicians Office Building, 170 Manning Drive, Campus Box #7235Chapel HillNC27599-7235

Résumé

In bladder urothelial carcinoma, ERBB2 mutations have been associated with favorable response to platinum-based neoadjuvant chemotherapy. However, this association has not been reported in upper tract urothelial carcinoma (UTUC). We describe an excellent response to cisplatin-based chemotherapy in metastatic UTUC with an ERBB2 mutation. Our patient is a 54-year-old female with metastatic UTUC who received systemic cisplatin and gemcitabine. Postchemotherapy imaging demonstrated decreased size of pyelocaliceal mass and decreased retroperitoneal adenopathy compared to initial imaging. Surgical pathology from consolidative resection showed 3 mm residual renal tumor and no viable lymph node disease. Genomic testing demonstrated an ERBB2 gain of function mutation.

Le texte complet de cet article est disponible en PDF.

Plan

CASE REPORT/CASE PRESENTATION

DISCUSSION

CONCLUSION

Funding Support:This work was supported by funding from the National Institutes of Health (UNC-Integrated Translational Oncology Program T32-CA244125 to UNC/khg).

Export

Vol 184

P. 75-78 - février 2024 Retour au numéro

Article précédent

A Targeted, Personalized Management Strategy in Advanced Penile Squamous Cell Carcinoma
Levi C. Holland, Thomas S. Gerald, Bailey Brooks, Vitaly Margulis

| Article suivant

Genomic Evolution of Oligometastatic Clear Cell Renal Cell Carcinoma Presenting Two Decades Following Radical Nephrectomy
Robert Wang, Nicole Uzzo, Raju Chelluri, Nicholas Mackrides, Hormoz Ehya, Jianming Pei, Don A. Baldwin, Mariusz A. Wasik, Shuanzeng Wei, Robert Uzzo

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report - 27/02/24

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL